Effect of teriparatide [rhPTH(1,34)] and calcitonin on intertransverse process fusion in a rabbit model

Spine

Volumn 35, Issue 2, 2010, Pages 146-152

  Lehman Jr , Ronald A ^a   Dmitriev, Anton E ^a   Cardoso, Mario J ^a   Helgeson, Melvin D ^a   Christensen, Christine L ^b   Raymond, JoLynne W ^b   Eckel, Tobin T ^a   Riew, K Daniel ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

Calcitonin; Osteoporosis; Parathyroid hormone; Rabbit model; Teriparatide

Indexed keywords

CALCITONIN; ENROFLOXACIN; PARATHYROID HORMONE[1-34]; PLACEBO; SALCATONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRODESIS; ARTICLE; AUTOGRAFT; BONE GRAFT; CONTROLLED STUDY; DRUG POTENCY; HISTOPATHOLOGY; HORMONAL THERAPY; ILIAC CREST; JOINT FUNCTION; LUMBAR SPINE; NONHUMAN; POSTOPERATIVE CARE; PRIORITY JOURNAL; RABBIT; RANGE OF MOTION; ROTATION; SCORING SYSTEM; SPINE FUSION; SPINE RADIOGRAPHY; VERTEBRA;

ANIMALS; BIOMECHANICS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE TRANSPLANTATION; CALCITONIN; CHI-SQUARE DISTRIBUTION; LUMBAR VERTEBRAE; RABBITS; RANDOM ALLOCATION; RANGE OF MOTION, ARTICULAR; SPINAL FUSION; STAINING AND LABELING; TERIPARATIDE; WOUND HEALING;

EID: 77749252823     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181b71a96     Document Type: Article

References (41)

1. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305-11.
2. Delmas PD, Fraser M. Strong bones in later life: luxury or necessity? Bull World Health Organ 1999;77:416-22.
3. Steinmann JC, Herkowitz HN. Pseudarthrosis of the spine. Clin Orthop Relat Res 1992;284:80-90.
4. Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005;20:1244-53.
5. Burr DB, Hirano T, Turner CH, et al. Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariecto-mized cynomolgus monkeys. J Bone Miner Res 2001;16:157-65.
6. Cosman F. The prevention and treatment of osteoporosis: a review. Med-GenMed 2005;7:73.
7. Doggrell SA. Present and future pharmacotherapy for osteoporosis. Drugs Today (Barc) 2003;39:633-57.
8. Genant HK, Siris E, Crans GG, et al. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone 2005;37:170-4.
9. Hirano T, Burr DB, Cain RL, et al. Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34). Calcif Tissue Int 2000;66:456-60.
10. Kneissel M, Boyde A, Gasser JA. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathy-roid hormone (PTH) analog SDZ PTS 893 or human PTH (1-34). Bone 2001;28:237-50.
11. Ma YL, Bryant HU, Zeng Q, et al. Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats. J Bone Miner Metab 2005;23(suppl):62-8.
12. Marx UC, Adermann K, Bayer P, et al. Solution structures of human para-thyroid hormone fragments hPTH(1-34) and hPTH(1-39) and bovine para-thyroid hormone fragment bPTH(1-37). Biochem Biophys Res Commun 2000;267:213-20.
13. Mashiba T, Burr DB, Turner CH, et al. Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical prop-erties of cortical bone during the first remodeling cycle in rabbits. Bone 2001;28:538-47.
14. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8.
15. Pande I, Hosking DJ. Oral antiresorptive therapy. Curr Osteoporos Rep 2004;2:116-22.
16. Pande I, Hosking DJ. Oral antiresorptive therapy. Curr Rheumatol Rep 2005;7:71-7.
17. Suzuki Y, Nagase Y, Iga K, et al. Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH(1-34). J Pharm Sci 2002;91:350-61.
18. Aldini NN, Caliceti P, Lora S, et al. Calcitonin release system in the treatment of experimental osteoporosis: histomorphometric evaluation. J Orthop Res 2001;19:955-61.
19. Babat LB, McLain R, Milks R, et al. The effects of the antiresorptive agents calcitonin and pamidronate on spine fusion in a rabbit model. Spine J 2005; 5:542-7.
20. Boden SD, Schimandle JH, Hutton WC. An experimental lumbar intertrans-verse process spinal fusion model: radiographic, histologic, and biomechanical healing characteristics. Spine 1995;20:412-20.
21. Erulkar JS, Grauer JN, Patel TC, et al. Flexibility analysis of posterolateral fusions in a New Zealand white rabbit model. Spine 2001;26:1125-30.
22. Emery SE, Brazinski MS, Koka A. The biological and biomechanical effects of irradiation on anterior spinal bone grafts: a canine model. J Bone Joint Surg 1994;76:540-8.
23. Ebeling PR, Russell RG. Teriparatide (rhPTH 1-34) for the treatment of osteoporosis. Int J Clin Pract 2003;57:710-8.
24. Hwang JS, Tu ST, Yang TS, et al. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006;17:373-8.
25. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocor-ticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39.
26. Carter PH, Schipani E. The roles of parathyroid hormone and calcitonin in bone remodeling: prospects for novel therapeutics. Endocr Metab Immune Disord Drug Targets 2006;6:59-76.
27. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
28. Cappuzzo KA, Delafuente JC. Teriparatide for severe osteoporosis. Ann Pharmacother 2004;38:294-302.
29. Einhorn TA, O'Keefe RJ, Buckwalter JA, eds. Orthopaedic Basic Science. 3rd ed. Rosemont, IL: AAOS; 2007.
30. Rehman Q, Lang TF, Arnaud CD, et al. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteo-poros Int 2003;14:77-81.
31. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone struc-ture. J Bone Miner Res 2003;18:1932-41.
32. Lane NE, Sanchez S, Genant HK, et al. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocrticoid-induced osteoporosis. Osteoporos Int 2000;11:434-42.
33. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
34. Orwoll ES, Scheele WH, Adami PS, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteopo-rosis. J Bone Miner Res 2003;18:9-17.
35. Brixen KT, Christensen PM, Ejersted C, et al. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Basic Clin Pharm Toxic 2004;94:260-70.
36. Stroup J, Kane MP, Abu-Baker AM. Teriparatide in the treatment of osteo-porosis. Am J Health Syst Pharm 2008;65:532-9.
37. Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-51.
38. Kaufman JM, Orwoll E, San Martin J, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005;16:510-6.
39. Kung AW, Pasion EG, Sofiyan M, et al. A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin 2006;22:929-37.
40. Gardner MJ, van der Meulen MC, Carson J, et al. Role of parathyroid hormone in the mechanosensitivity of fracture healing. J Orthop Res 2007; 25:1474-80.
41. Tsiridis E, Morgan EF, Bancroft JM, et al. Effects of OP-1 and PTH in a new experimental model for the study of metaphyseal bone healing. J Orthop Res 2007;25:1193-203.